Test Code ALAD Aminolevulinic Acid Dehydratase, Whole Blood
Reporting Name
ALA Dehydratase, WBUseful For
Preferred confirmation test for the diagnosis of aminolevulinic acid dehydratase deficiency porphyria
This test is not useful for detecting lead intoxication.
Testing Algorithm
The following algorithms are available:
-Porphyria (Acute) Testing Algorithm
Method Name
Enzymatic End point/Spectrofluorometric
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Whole bloodOrdering Guidance
This assay is not useful in assessment of lead intoxication as it reactivates aminolevulinic acid dehydratase that has been inhibited by lead. The preferred test for lead toxicity is PBDV / Lead, Venous, with Demographics, Blood.
Necessary Information
1. Patient’s age is required
2. Include a list of medications the patient is currently taking.
Specimen Required
Patient Preparation: Patient must not consume any alcohol for 24 hours before specimen collection. This is essential as ethanol suppresses aminolevulinic acid dehydratase activity, leading to false-positive results.
Container/Tube:
Preferred: Green top (sodium heparin)
Acceptable: Lavender top (EDTA) or green top (lithium heparin)
Specimen Volume: Full tube 4 mL
Collection Instructions: Refrigerate specimen as soon as possible.
Specimen Minimum Volume
3 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole blood | Refrigerated (preferred) | 7 days | |
Ambient | 4 days |
Reject Due To
Gross hemolysis | Reject |
Special Instructions
Reference Values
Reference ranges have not been established for patients who are younger than 16 years of age.
≥4.0 nmol/L/sec
3.5-3.9 nmol/L/sec (indeterminate)
<3.5 nmol/L/sec (diminished)
Day(s) Performed
Thursday
CPT Code Information
82657
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
ALAD | ALA Dehydratase, WB | 12916-3 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
4021 | ALA Dehydratase | 12916-3 |
28399 | Interpretation | 59462-2 |
606468 | Reviewed By | 18771-6 |
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Report Available
2 to 8 daysForms
New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available: